Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Condition(s)
Brain / CNS Tumors

Age Group
10-17 years 18-26 years

Phase(s)
1

Biological treatment cell Biological
IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes
Trial Summary & Details
Ages: 12 Years to 75 Years
Condition: Malignant Glioma, Refractory Brain Neoplasm, Recurrent Brain Neoplasm, Glioblastoma

This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient’s blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.

Results & References
Status
Recruiting
Location(s)
City of Hope Medical Center, Duarte, CA

Sponsors/Collaborators:
City of Hope Medical Center, National Cancer Institute (NCI), Gateway for Cancer Research, Mustang Bio, Inc.
Contact
Paige Myers-McNamara
626-218-9393